Rejoni, Inc., a clinical-stage medical technology company focused on uterine health, has secured $25 million in financing to support the regulatory, manufacturing and commercial preparation of its Juveena® Hydrogel System, an investigational device designed to address complications associated with intrauterine surgery.
The financing included participation from new and existing investors, including Clavyst Bio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta Group. The funding will help position the Bedford, Massachusetts-based company for a potential commercial launch following U.S. Food and Drug Administration approval.
Rejoni plans to use the proceeds to expand manufacturing and supply chain capabilities, strengthen market access initiatives and increase physician and patient engagement efforts as it prepares for commercialization. The investment marks a significant step in the company’s transition from clinical development to launch readiness.
“Uterine health has been underserved for too long, and this financing puts us in a position to change that,” said John Nealon, Chief Executive Officer of Rejoni. “We are building the infrastructure, commercial readiness, market access and physician engagement to ensure we can move quickly when Juveena is approved.”
The company’s lead product, the Juveena Hydrogel System, is designed to support healing within the uterine cavity following endometrial trauma associated with intrauterine surgical procedures. Such procedures can lead to the formation of intrauterine adhesions, a condition that may impact reproductive health and quality of life for affected patients.
Juveena utilizes a proprietary transcervical catheter to deliver a temporary hydrogel spacer into the uterine cavity during the healing process. The hydrogel is intended to help reduce the incidence and severity of intrauterine adhesions by maintaining separation of tissue surfaces while healing occurs. The product remains investigational and has not yet received FDA approval.
The financing reflects growing investor interest in women’s health technologies, an area that has historically received less attention and capital relative to other healthcare sectors despite significant unmet clinical needs. Investors increasingly view the category as an attractive opportunity for innovation, particularly in areas where treatment options remain limited.
“This financing marks an important milestone in Rejoni’s evolution from building the science to preparing for launch,” said Amar Sawhney, founder and chairman of Rejoni. “John and the team have the experience and drive to execute on this opportunity, and I remain fully committed to this mission.”
Sawhney is a veteran medical technology entrepreneur whose previous ventures include Confluent Surgical, Ocular Therapeutix and Augmenix. Rejoni, founded in 2020, represents his latest effort to commercialize proprietary biomaterials technology aimed at addressing unmet needs in gynecological care.
The new capital will allow Rejoni to invest not only in manufacturing scale-up but also in the commercial infrastructure required to support physician adoption and patient awareness. Those investments are increasingly important for medical device companies approaching regulatory milestones, particularly in specialized healthcare markets where education and clinical engagement play a critical role in market adoption.
As the company advances toward potential FDA approval, Rejoni is positioning itself to enter a segment of women’s health focused on improving outcomes following gynecological procedures. The financing provides the resources needed to expand operational capabilities and prepare for commercialization while continuing efforts to bring new treatment options to a historically underserved area of healthcare.
With regulatory preparation, manufacturing expansion and market development now underway, Rejoni is entering a new phase of growth as it works to bring the Juveena Hydrogel System to physicians and patients across the United States.
